

REMARKS

Support for the new claims can be found throughout the specification, e.g., on pages 4-5 and 18, respectively, for the terms "biologically," "immunologically" and antigenically active. No new matter has been added by these amendments. Applicant respectfully requests entry of the present amendment prior to examination of the above-identified application.

Applicant respectfully requests that the entirety of the above claims be examined together in the present application. It is noted that the polynucleotides of original claims 11 and 12, expression vectors and host cells containing them, and methods of making the polypeptide encoded by the polynucleotides have already been examined and issued in the parent application. It is submitted that claims 13 and 17 should have been examined with those claims, as they are dependent composition or method claims which depended from allowed claim 12. It is respectfully submitted that there is little if any additional burden on the Examiner to examine and allow those claims in addition to any other claims which might be elected in the present application.

Moreover, it is noted that there the newly added claims include process/method claims depending from polypeptide product claims, and product-by-process claims which overlap to some extent with originally filed product claims. Applicant therefore respectfully submits that a search of the polypeptide claims and the new process and product-by-process claims would substantially overlap with a search for other originally filed product, e.g., antibody, claims, and that a search for the full scope of the remaining claims would therefore pose no undue additional burden on the Examiner. Examination in accordance with this fact is therefore respectfully requested.

If there are any questions regarding the above, the Examiner is invited to call Applicants' Attorney at (650) 845-4639.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. **This form is enclosed in duplicate.**

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 3 Aug 1999



Diana Hamlet-Cox, Ph.D.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886